- Discovery of thienothiazolocarboxamide analogues as novel anti-tubercular agent
-
In order to identify anti-tubercular agents with a novel scaffold, commercial libraries of small organic compounds were screened against a fluorescent strain of Mycobacterium tuberculosis H37Rv, using a dual phenotypic assay. Compounds were assessed again
- Carla, Virginia,Choi, Inhee,Choi, Junghwan,Delorme, Vincent,Heo, Jinyeong,Jea Seo, Jeong,Jin, Guanghai,Kang, Juhee,Kang, Sunhee,Kim, Jaeseung,Lee, Aram,Lee, Honggun,Lee, Sumi,Mi Kim, Young,Park, Kaapjoo,Park, Sinyoung,Seo, Mooyoung,Shum, David,Woo, Minjeong
-
-
- Recyclable Pd/CuFe2O4 nanowires: A highly active catalyst for C-C couplings and synthesis of benzofuran derivatives
-
Pd/CuFe2O4 nanowire-catalyzed cross coupling transformations are described. Notably, these reactions showed excellent functional group tolerance. Further, the protocol is applied to a one-pot synthesis of benzofurans via a Sonogashira coupling and intramolecular etherification sequence. The catalyst was reused and found to maintain its activity and stability.
- Lakshminarayana, Bhairi,Chakraborty, Jhonti,Satyanarayana,Subrahmanyam, Ch.
-
p. 21030 - 21039
(2018/06/13)
-
- Synthesis and evaluation of the anticoccidial activity of trifluoropyrido[1,2-a]pyrimidin-2-one derivatives
-
Screening of our chemical library to discover new molecules exhibiting in vitro activity against the invasion of host cells by Eimeria tenella revealed a lead compound with an IC50 of 15 μM. Structure-activity relationship studies were conducted with 34 newly synthesized compounds to identify more active molecules and enhance in vitro activity against the parasite. Four compounds were more effective in inhibiting MDBK cell invasion in vitro than the lead compound.
- Silpa, Laurence,Niepceron, Alisson,Laurent, Fabrice,Brossier, Fabien,Pénichon, Mélanie,Enguehard-Gueiffier, Cécile,Abarbri, Mohamed,Silvestre, Anne,Petrignet, Julien
-
p. 114 - 120
(2015/12/18)
-
- WNT PATHWAY MODULATORS
-
The present invention relates to dihydropyrazolo[l,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.
- -
-
Paragraph 0251; 0252; 0275; 0276
(2015/07/07)
-
- Peptide deformylase inhibitors
-
The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.
- -
-
Page/Page column
(2014/12/09)
-
- PEPTIDE DEFORMYLASE INHIBITORS
-
The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhi-bition of bacterial peptide deformylase (PDF) activity
- -
-
Page/Page column
(2014/02/15)
-
- Aryl pyridines and methods of their use
-
Aryl pyridines, compositions comprising them, and methods of their use for the treatment, prevention and management of a variety of diseases and disorders are disclosed.
- -
-
Page/Page column 8
(2008/06/13)
-
- New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes
-
Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof used in the form of pharmaceutical compositions.
- -
-
Page/Page column 13
(2008/06/13)
-
- Compounds that modulate PPAR activity and methods of preparation
-
This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
- -
-
-